A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy

The abnormal activation of epidermal growth factor receptor (EGFR) drives the development of non-small cell lung cancer (NSCLC). The EGFR-targeting tyrosine kinase inhibitor osimertinib is frequently used to clinically treat NSCLC and exhibits marked efficacy in patients with NSCLC who have an EGFR...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Bin Xu, Fanjun Zeng, Jialong Deng, Lintong Yao, Shengbo Liu, Hengliang Hou, Yucheng Huang, Hongyuan Zhu, Shaowei Wu, Qiaxuan Li, Weijie Zhan, Hongrui Qiu, Huili Wang, Yundong Li, Xianzhu Yang, Ziyang Cao, Yu Zhang, Haiyu Zhou
Formato:	Artigo
Idioma:	Inglês
Publicado em:	KeAi Communications Co., Ltd. 2023-09-01
coleção:	Bioactive Materials
Assuntos:	Biomimetic nanoparticles Membrane targeting EGFR mutation Tyrosine kinase inhibitor Intracellular drug delivery Clinical efficacy
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2452199X23001238
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!